Scott Rocklage – The Race For A Cure
Scott Rocklage, M.D. attended the University of California in Berkeley. While there he earned a Bachelor of Science Degree in Chemistry. He received his Ph.D. at Massachusetts Institute of Technology (MIT). Read more: Scott Rocklage | Bloomberg and Scott Rocklage | Crunchbase
Scott Rocklage, M.D. has over 30 years of healthcare management experience. Dr. Rocklage responsible for the FDA approval the medications Cubicin, Teslascan and Omniscan. He has co-invented and invented over 30 U.S. patents. In Addition, he continues to submit medications for clinical trials. He is consistently written articles for peer review publication.
Since 2004 Dr. Scott Rocklage is currently serving as the Managing Partner of 5AM Ventures. He is a powerhouse of leadership, he has had several positions in leading companies to success. He was the Chairman and CEO of Cubist Pharmaceuticals and served as President and CEO of Nycomed Salutar. He was also the Board Chairman for Relypsa, Achaogen and Novira.
He is currently the Chairman of the Board for Cidara, Kinestral and Rennovia. He was the Executive Chairman of Ilypsa, Miikana and Semprus. He was also at one time serving as the Independent Director of Zalicus, Inc. Dr. Rocklage works at the Boston, Massachusetts office of 5AM Ventures.
Now a days Dr. Rocklage can be found rallying support and funding for Myotonic Dystrophy, which is classified as the leading cause of muscular dystrophy. Funding for this disease is important because of how it affects the muscles, heart, and gastrointestinal system of patients.
In addition, patients respiratory and central nervous systems become defective. This disease affects the entire family; that is why it is important to find a cure. With the help of other ventures, Expansion Therapeutics and Dr. Rocklage; a cure is sure to be found.